PMID- 34624650
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20220308
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 101
IP  - Pt A
DP  - 2021 Dec
TI  - Development and validation of a ferroptosis-related prognostic model for the 
      prediction of progression-free survival and immune microenvironment in patients 
      with papillary thyroid carcinoma.
PG  - 108156
LID - S1567-5769(21)00792-X [pii]
LID - 10.1016/j.intimp.2021.108156 [doi]
AB  - BACKGROUND: Ferroptosis is an iron-dependent and regulated cell death that has 
      been widely reported in a variety of malignancies. The overall survival of 
      papillary thyroid cancer (PTC) is excellent, but the identification of patients 
      with poor prognosis still faces challenges. Nevertheless, whether 
      ferroptosis-related genes (FRGs) can be used to screen high-risk patients is not 
      clear. METHODS: We obtained the clinical data of patients with PTC and FRGs from 
      the UCSC Xena platform and the FerrDb respectively. Differentially expressed 
      genes (DEGs) of FRGs were obtained from the entire The Cancer Genome Atlas 
      (TCGA). Subsequently, the entire TCGA dataset was randomly split into two 
      subsets: training and test datasets. Based on DEGs, we constructed a predictive 
      model which was tested in the test dataset and the entire TCGA dataset to predict 
      progression-free survival (PFS). Patients were categorized into high- or low-risk 
      groups based on their median risk score. We analyzed differences in some aspects, 
      including pathway enrichment analysis, single-sample Gene Set Enrichment Analysis 
      (ssGSEA), tumor microenvironment (TME), human leukocyte antigen (HLA) genes, and 
      tumor mutation burden (TMB) analyses, between high-risk and low-risk groups. 
      RESULTS: A predictive model with three FRGs (HSPA5, AURKA, and TSC22D3) was 
      constructed. Patients in the high-risk group had worse PFS compared with patients 
      in the low-risk group. Functional analysis results revealed that ssGSEA, immune 
      cell infiltration, TME, HLA, and TMB were closely associated with ferroptosis. 
      CONCLUSION: The prognostic model constructed in this study can effectively 
      predict PFS for patients with PTC.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Huang, Yinde
AU  - Huang Y
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China.
FAU - Xie, Zhenyu
AU  - Xie Z
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China.
FAU - Li, Xin
AU  - Li X
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China.
FAU - Chen, Wenbin
AU  - Chen W
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China.
FAU - He, Yuzhen
AU  - He Y
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China.
FAU - Wu, Song
AU  - Wu S
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China.
FAU - Li, Xinyang
AU  - Li X
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China.
FAU - Hou, Bingchen
AU  - Hou B
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China.
FAU - Sun, Jianjian
AU  - Sun J
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China.
FAU - Wang, Shiyue
AU  - Wang S
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China.
FAU - He, Yuchen
AU  - He Y
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China.
FAU - Jiang, Han
AU  - Jiang H
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China.
FAU - Lun, Yu
AU  - Lun Y
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China.
FAU - Zhang, Jian
AU  - Zhang J
AD  - Department of Vascular and Thyroid Surgery, The First Hospital, China Medical 
      University, Shenyang, Liaoning 110001, China. Electronic address: 
      jianzhang@cmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20211006
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Endoplasmic Reticulum Chaperone BiP)
RN  - 0 (HSPA5 protein, human)
RN  - 0 (TSC22D3 protein, human)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.11.1 (AURKA protein, human)
RN  - EC 2.7.11.1 (Aurora Kinase A)
SB  - IM
MH  - Aurora Kinase A/genetics
MH  - Biomarkers, Tumor/*genetics
MH  - Datasets as Topic
MH  - Endoplasmic Reticulum Chaperone BiP/genetics
MH  - Female
MH  - Ferroptosis/*genetics/immunology
MH  - Follow-Up Studies
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic/*immunology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Progression-Free Survival
MH  - Risk Assessment/methods
MH  - Thyroid Cancer, Papillary/genetics/immunology/*mortality/therapy
MH  - Thyroid Gland/immunology/pathology
MH  - Thyroid Neoplasms/genetics/immunology/*mortality/therapy
MH  - Transcription Factors/genetics
MH  - Tumor Microenvironment/genetics/immunology
OTO - NOTNLM
OT  - Ferroptosis
OT  - Papillary thyroid carcinoma
OT  - Progression-free survival
OT  - Single-sample gene set enrichment analysis
OT  - Tumor microenvironment
OT  - Tumor mutation burden
EDAT- 2021/10/09 06:00
MHDA- 2022/03/09 06:00
CRDT- 2021/10/08 20:23
PHST- 2021/07/27 00:00 [received]
PHST- 2021/08/31 00:00 [revised]
PHST- 2021/09/11 00:00 [accepted]
PHST- 2021/10/09 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
PHST- 2021/10/08 20:23 [entrez]
AID - S1567-5769(21)00792-X [pii]
AID - 10.1016/j.intimp.2021.108156 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2021 Dec;101(Pt A):108156. doi: 
      10.1016/j.intimp.2021.108156. Epub 2021 Oct 6.